PT83939A - Method for the production of human placenta angiogenic factor capable of stimulating capillary endothelial cell protease synthesis dna synthesis and migration - Google Patents

Method for the production of human placenta angiogenic factor capable of stimulating capillary endothelial cell protease synthesis dna synthesis and migration

Info

Publication number
PT83939A
PT83939A PT83939A PT8393986A PT83939A PT 83939 A PT83939 A PT 83939A PT 83939 A PT83939 A PT 83939A PT 8393986 A PT8393986 A PT 8393986A PT 83939 A PT83939 A PT 83939A
Authority
PT
Portugal
Prior art keywords
angiogenic factor
migration
synthesis
production
endothelial cell
Prior art date
Application number
PT83939A
Other languages
English (en)
Other versions
PT83939B (pt
Inventor
David A Moscatelli
Daniel B Rifkin
Andreas Sommer
Original Assignee
Synergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT83939(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synergen Inc filed Critical Synergen Inc
Publication of PT83939A publication Critical patent/PT83939A/pt
Publication of PT83939B publication Critical patent/PT83939B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT83939A 1985-12-17 1986-12-16 Metodo para a producao de factor angiogenico da placenta humana capaz de estimular a sintese de proteases, sintese de dna e migracao de celulas endoteliais capilares PT83939B (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80987385A 1985-12-17 1985-12-17
US88855486A 1986-07-16 1986-07-16
US89582986A 1986-08-12 1986-08-12

Publications (2)

Publication Number Publication Date
PT83939A true PT83939A (en) 1987-01-01
PT83939B PT83939B (pt) 1989-05-31

Family

ID=27420052

Family Applications (1)

Application Number Title Priority Date Filing Date
PT83939A PT83939B (pt) 1985-12-17 1986-12-16 Metodo para a producao de factor angiogenico da placenta humana capaz de estimular a sintese de proteases, sintese de dna e migracao de celulas endoteliais capilares

Country Status (15)

Country Link
EP (1) EP0226181B1 (pt)
JP (1) JPH10262668A (pt)
KR (1) KR960015442B1 (pt)
AT (1) ATE107315T1 (pt)
AU (2) AU6774887A (pt)
DE (1) DE3689921T2 (pt)
DK (1) DK424387D0 (pt)
ES (1) ES2056787T3 (pt)
FI (1) FI93843C (pt)
IE (1) IE863281L (pt)
IL (1) IL80944A (pt)
NO (1) NO177859C (pt)
NZ (1) NZ218631A (pt)
PT (1) PT83939B (pt)
WO (1) WO1987003885A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
CA2002261A1 (en) * 1988-11-07 1990-05-07 Andreas Sommer High molecular weight human angiogenic factors
WO1993015753A1 (fr) * 1992-02-14 1993-08-19 Kaken Pharmaceutical Co., Ltd. Medicament contre les maladies des voies aeriennes
GB9203533D0 (en) * 1992-02-19 1992-04-08 Erba Carlo Spa Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
EP1541674B9 (en) 2002-06-18 2011-09-14 Eisai R&D Management Co., Ltd. Primary cultured adipocytes for gene therapy
WO2007038686A2 (en) * 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
CN111100191A (zh) * 2018-10-26 2020-05-05 神威药业集团有限公司 源于人胎盘的活性蛋白质或多肽及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4225670A (en) * 1978-12-29 1980-09-30 Monsanto Company Production of tumor angiogenesis factor by cell culture
US4209587A (en) * 1978-12-29 1980-06-24 Monsanto Company Production of tumor angiogenesis factor by cell culture
DE3110560A1 (de) * 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
US4529590A (en) * 1982-12-27 1985-07-16 Leveen Robert F Production of angiogenetic factor
GB2146523B (en) * 1983-09-13 1987-01-07 Ward Page Faulk Preparation for stimulating growth of blood vessels prepared from amniochorionic tissue and macrophages
ATE222602T1 (de) * 1985-09-12 2002-09-15 Scios Inc Rekombinante fibroblasten-wachstums-faktoren
IL81650A0 (en) * 1986-02-24 1987-09-16 Robapharm Ag Purified human angiogenic factor,method for its preparation and pharmaceutical preparations

Also Published As

Publication number Publication date
EP0226181A3 (en) 1989-03-08
IL80944A0 (en) 1987-03-31
NO873437D0 (no) 1987-08-14
AU7629991A (en) 1991-08-08
AU650649B2 (en) 1994-06-30
KR960015442B1 (ko) 1996-11-14
FI882891A (fi) 1988-06-16
ATE107315T1 (de) 1994-07-15
DE3689921T2 (de) 1994-09-22
NO177859C (no) 1995-12-06
FI882891A0 (fi) 1988-06-16
PT83939B (pt) 1989-05-31
IE863281L (en) 1987-06-17
NZ218631A (en) 1991-07-26
IL80944A (en) 1994-10-07
DK424387A (da) 1987-08-14
NO873437L (no) 1987-08-14
DK424387D0 (da) 1987-08-14
AU6774887A (en) 1987-07-15
DE3689921D1 (de) 1994-07-21
ES2056787T3 (es) 1994-10-16
FI93843C (fi) 1995-06-12
NO177859B (no) 1995-08-28
KR880700820A (ko) 1988-04-12
WO1987003885A1 (en) 1987-07-02
JPH10262668A (ja) 1998-10-06
EP0226181B1 (en) 1994-06-15
FI93843B (fi) 1995-02-28
EP0226181A2 (en) 1987-06-24

Similar Documents

Publication Publication Date Title
EP0259475A4 (en) RECOMBINANT HUMAN ENDOTHEL CELL GROWTH FACTOR.
NL930040I1 (nl) Humaan immuun interferon
NO177678C (no) Fremgangsmåte for fremstilling av et terapeutisk aktivt, rekombinant protein som har ASP-aktivitet, ekspresjonssystem samt DNA som koder for nevnte protein
ATE71632T1 (de) Cdns und gen fuer menschliches angiogenin (angiogenesis-faktor) und expression.
DE3873397D1 (de) Bifunktionelle proteine.
ATE131532T1 (de) Expression von biologisch-aktiven pdgf-analogen in eukaryotischen zellen
PT83939A (en) Method for the production of human placenta angiogenic factor capable of stimulating capillary endothelial cell protease synthesis dna synthesis and migration
DK288789A (da) Peptider og syreadditionssalte deraf, deres fremstilling og anvendelse
KR900005994A (ko) 혈소판 감소증 또는 혈소판 기능장애로 인한 질병 치료용 약학적 제제
ES8605296A1 (es) Procedimiento de producir factor viii-r humano
IT1226713B (it) Procedimento per la preparazione di interleuchina 1 beta umana ricombinante in forma omogenea.
PT85226A (en) Process for the preparation of novel trombolytic proteins

Legal Events

Date Code Title Description
MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19990531